SCHEMBL24656151

SCHEMBL24656151

CC(C)(C)c1cc(-n2nccn2)cc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.41
GABRB2 P47870 2/20 0.39
GABRA1 P14867 1/20 0.39
ADRB1 P08588 1/20 0.37
FFAR4 Q5NUL3 1/20 0.36
CNR1 P21554 1/20 0.34
XPO1 O14980 1/20 0.34
GABRA2 P47869 1/20 0.33
NR2E1 Q9Y466 1/20 0.33
JUN P05412 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
NOTUM Q6P988 1/20 0.33
KIF11 P52732 1/20 0.33
NPBWR1 P48145 1/20 0.32
MCHR1 Q99705 1/20 0.32
PRKCZ Q05513 1/20 0.32
CYP11B2 P19099 2/20 0.31
CES2 O00748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21030752 0.81 NR2E1 (0.36) ARADRB1FFAR4CNR1XPO1
SCHEMBL24656148 0.81 KAT6A (0.36) GABRB2GABRA1CYP11B2CYP11B1
SCHEMBL24656150 0.79 GABRA1 (0.35) GABRB2GABRA1
SCHEMBL8739094 0.78 NR2E1 (0.50) ARADRB1CNR1NR2E1JUN
SCHEMBL21030428 0.77 CNR1 (0.33) ARADRB1CNR1NR2E1NOTUM
SCHEMBL22861023 0.77 GABRB2 (0.52) ARGABRB2GABRA1ADRB1XPO1
SCHEMBL1104677 0.77 GABRB2 (0.52) ARGABRB2GABRA1ADRB1XPO1
SCHEMBL24656661 0.76 NR2E1 (0.44) ARGABRB2GABRA1ADRB1FFAR4
SCHEMBL29935724 0.74 CNR1 (0.35) ADRB1CNR1XPO1JUNNFKB1
SCHEMBL20996728 0.73 CES2 (0.43) CNR1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP AR 3305/4885GABRB2 482/4885GABRA1 764/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP AR 3305/4885GABRB2 482/4885GABRA1 764/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP AR 3305/4885GABRB2 482/4885GABRA1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.